MedTrace Logo

Single Ascending Dose Study of AMG 570 in Healthy Subjects

NCT02618967 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-05-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to obtain initial information on the safety and tolerability (effects good or bad), pharmacokinetics (what the body does to the drug), and pharmacodynamics (what the drug does to the body) of a single dose of AMG 570.

Conditions

Interventions

BIOLOGICAL

AMG 570

7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.

BIOLOGICAL

AMG 570 Matching Placebo

Placebo administered as single dose subcutaneous in healthy volunteers.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-28
Primary Completion
2018-09-06
Completion
2018-12-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02618967 on ClinicalTrials.gov